2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Genomics, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphomas, Measurable Residual Disease, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5413 Zimberelimab (PD-1 inhibitor) and chidamide (histone deacetylase inhibitor) combined with rituximab in relapsed/refractory diffuse large B‑cell lymphoma: A prospective, multicenter, phase II clinical study(PCR trial)

Gao Yan, PhD, Xue-Ping Li2, Xuan-Ye Zhang3, Jicheng Hong4, Xiaolei Wei5, Qichun Cai, PhD6, Li-Qin Ping7, Huiqiang Huang, MD, PhD8
1 Sun Yat-sen University Cancer Center, Guangzhou, China
2 Sun Yat-sen University Cancer Center, Guangzhou, China
3 Sun Yat-sen University Cancer Center, Guangzhou, China
4 Sun Yat-sen University Cancer Center, Guangzhou, China
5 Nanfang Hospital, Southern Medical University, Guangzhou, China
6 Cancer Center, Clifford Hospital, Guangzhou, China
7 The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China
8 Sun Yat-sen University Cancer Center, Guangzhou, China

Background:
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma. Standard R-CHOP cures ~60% of patients, but 30%–40% relapse and ~10% are primary refractory. For relapsed/refractory (R/R) DLBCL, salvage chemotherapy has limited efficacy; the SCHOLAR-1 study reported an objective response rate (ORR) of only 26% and median OS of 6.3 months in refractory patients. Novel strategies are needed. Chidamide monotherapy showed ORR 25% in R/R DLBCL; PD-1 inhibitors have modest activity; rituximab retreatment is limited by CD20 downregulation. Mechanistically, chidamide upregulates CD20 via epigenetic modulation and remodels the immune microenvironment to enhance PD-1 blockade, while PD-1 inhibition relieves immunosuppression and potentiates rituximab-dependent ADCC. Thus, triple combination is synergistic. No prior study has reported this regimen. This trial evaluates efficacy and safety of chidamide plus PD-1 inhibitor and rituximab.

Methods:
Single-arm, open-label phase II trial (NCT05115409). Eligible: age≥18, histologically confirmed DLBCL (including transformed follicular and high-grade B-cell lymphoma), CD20-positive, refractory/relapsed after at least 2 cycles of a standard first-line rituximab-containing regimen. Refractory defined as failure to achieve PR with last therapy or progression within 6 months after last regimen. Induction: 6 cycles of PCR (zimberelimab 240 mg IV day1; chidamide 30 mg twice weekly days1–21; rituximab 375 mg/m² IV day1). Patients achieving CR or PR received maintenance with same PCR regimen for 1 year (monthly, 12 cycles). CR patients could undergo ASCT. Sample size: assuming expected ORR 50% vs historical 30%, one-sided α=0.0499, β=0.1968, total 46 (two-stage: first 15; if ≤5 responses, stop; else continue; if total responders >18, effective). Enrolled 50 accounting for 10% dropout. Primary endpoint ORR per LYRIC 2016; secondary PFS, OS, safety per CTCAE v5.0.

Results:
Between July 2022 and December 2025, 50 patients were enrolled from 3 Chinese cancer centers. The median age was 55 years (range, 23–85); 60% (n=30) were female, and 72% (n=36) had an Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥1. Advanced stage disease was present in 58% (n=29), and 78% (n=39) of patients were refractory to prior therapy. The IPI score was ≥3 in 26% (n=13), and 60% (n=30) had the non-germinal center B-cell (non-GCB) subtype by Hans algorithm. Double expressor (MYC and BCL2 co-expression) was observed in 5 patients (10%), and double-hit (MYC and BCL2 and/or BCL6 rearrangements) in 2 patients (4%). High proliferative index (Ki-67 >90%) was noted in 14 patients (28%), and bulky disease (>7.5 cm) in 11 patients (22%). The median number of prior lines of therapy was 3 (range, 2–9). Prior treatments included PD-1/PD-L1 inhibitors in 19 patients (38%), ASCT in 5 (10%), CD3×CD20 bispecific antibodies in 5 (10%), and CAR T-cell therapy in 3 (6%). The median number of PCR cycles administered was 4 (range, 1–12). The overall ORR was 50.0% (25/50), with a CR rate of 46.0% (23/50). In subgroup analyses, ORR was higher in patients without bulky disease (56.4% vs. 36.4% in bulky), in relapsed versus refractory patients (63.6% vs. 46.2%), and in those with Ki-67 <90% (55.6% vs. 35.7% in Ki-67 ≥90%). ORR was comparable between GCB and non-GCB subtypes (40% vs. 40%) and between patients with or without prior PD-1 inhibitor exposure (57.9% vs. 45.2%). Among double expressor patients, ORR was 40% (2/5), while double-hit patients achieved an ORR of 100% (2/2). With a median follow-up of 11.9 months (range, 3.2–65.0), the 1-year OS rate was 70.2% and the 1-year PFS rate was 43.0%; the median PFS was 4.3 months. Regarding safety, the most common all-grade adverse events were agranulocytosis (46%), anemia (28%), and thrombocytopenia (20%). Immune-related adverse events included rash (10%) and interstitial pneumonia (10%). Grade ≥3 AEs occurred in a subset of patients, with the most frequent being neutropenia (34%), which was reversible with growth factor support. No treatment-related deaths were reported.

Conclusions:
The PCR study successfully met its prespecified primary efficacy endpoint. The regimen showed encouraging activity across various high-risk subgroups, with manageable and non-cumulative toxicity.These findings support further evaluation of the PCR regimen in earlier lines of therapy and in combination with other novel agents. 

Huiqiang Huang, MD, PhD: No relevant conflicts of interest to declare.